China chip stocks rally on self-reliance bets, Nvidia scrutiny
Investing.com - JPMorgan maintained its Overweight rating and $35.00 price target on Upstream Bio (NASDAQ:UPB) as the company approaches multiple clinical readouts. The stock, currently trading at $13.63, has shown strong momentum with a 28% gain in the past week. According to InvestingPro data, analyst targets range from $35 to $75, suggesting significant upside potential.
The investment bank expects Upstream Bio to deliver positive Phase 2 results with its lead asset, verekitug, across multiple type 2 inflammatory conditions over the next nine months.
Data from the chronic rhinosinusitis with nasal polyps (CRSwNP) trial is expected this quarter, followed by severe asthma results in the first quarter of 2026.
JPMorgan noted that the severe asthma data should be "more inflective in nature," suggesting these results could have greater impact on the company’s outlook.
The firm highlighted that Upstream Bio has sufficient cash to fund operations through 2027, providing runway beyond these upcoming clinical milestones.
In other recent news, Upstream Bio has initiated a Phase 2 clinical trial for its drug candidate verekitug, aimed at treating chronic obstructive pulmonary disease (COPD). The VENTURE trial will evaluate the efficacy and safety of verekitug in approximately 670 adults with moderate-to-severe COPD, with participants receiving various doses over treatment periods ranging from 60 to 108 weeks. Additionally, Upstream Bio has appointed Stacy Price as the new Chief Technology Officer. Price brings over 25 years of experience in the biotech industry and will focus on expanding technical operations and product development, particularly for verekitug. Her previous roles include Chief Technology and Manufacturing Officer at Invivyd and Chief Technical Officer at Akouos. Price’s educational background includes degrees in Biochemical and Chemical Engineering from Tufts University. These developments highlight Upstream Bio’s ongoing efforts in advancing its drug pipeline and strengthening its leadership team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.